TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01345487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable Protein
Description: Vegetable protein in the form of fava beans/split peas

Intervention type: OTHER
Group type: OTHER
Intervention: Vegetable Protein
Description: Vegetable protein in the form of fava beans/split peas

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal protein
Description: Protein in the form of minced pork/beef
Study: NCT02483208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY81-8973
Description: BAY81-8973 infusion to analyze pharmacokinetics
Study: NCT04073953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPQ
Description: The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
Study: NCT02483208

Intervention type: DRUG
Group type: OTHER
Intervention: Advate
Description: Advate infusion to analyze pharmacokinetics.
Study: NCT01918774

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavior therapy for work success (CBTw)
Description: The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
Study: NCT04189159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMPT
Description: PROMPT treatment is consistent with the principles of motor learning, in that every session includes a blocked pre-practice followed by variable and distributed practice and a gradual, hierarchical increase of complexity. Speech motor goals are integrated in goals for language and functional communication. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided, in order to shape speech movements, to give information on sequencing and timing and to introduce constraints for the reduction of degrees of freedom at the articulators' level in favour of motor control.
Study: NCT01768013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90105
Description: Once daily for four weeks
Study: NCT01740726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: 18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
Study: NCT04073953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPQ
Description: The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
Study: NCT00268476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Study: NCT04073953

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
Study: NCT05011045

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Intervention: Neurocognitive Assessment
Description: Undergo neurocognitive function assessment

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT02804022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VPIA analgesia
Description: Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line with an anti-reflux valve to ensure precise drug administration and no backflow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line.
Study: NCT05927948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laight therapy, NICE V3.1 device
Description: Laight therapy is a non-invasive method of treatment for HS and acne developed in Germany which utilizes a combination of radiofrequency and intense pulsed light exposure. Three passes of the device, all coupled with radiofrequency, are used in the proposed treatment area. The first pass encompasses wavelengths between 420 nm and 1200 nm, the second between 510 nm and 1200 nm, and the third pass between 690 nm and 1200 nm.
Study: NCT03713619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: secukinumab
Description: Secukinumab 300mg every 2 or every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: secukinumab
Description: Secukinumab 300mg every 2 or every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300mg every 2 or every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300mg every 2 or every 4 weeks
Study: NCT02874885

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample
Study: NCT03444376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-188E
Description: GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: pembrolizumab(100mg/4mL/vial), Intravenous administration
Study: NCT05729685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval training
Description: The interval training group trained using the interval method. During the exercise sessions the participants ran each bout at an intensity corresponding to 90% of PTV. PTV was used to prescribe the exercise intensity at the INT group. The duration of the running-bouts was equal to ¼ of the individual time to exhaustion at 90% of PTV (determined during the CV testing) followed by passive rest equal to 2/3 of exercise duration. The duration of the exercise-bouts was individualized based on the time to exhaustion at 90% of PTV to reduce the between subject's variability. The participants terminated each exercise session when an RPE value of 17 was reached. Running bout duration and intensity were adjusted after 7 training sessions (during the 3rd week) following a reassessment of the time to exhaustion at 90% of the new PTV achieved during mid-testing as a result of training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous training
Description: The continuous group trained using the continuous method. During the training sessions the participants ran with an intensity corresponding to -2,5% of CV until they reported a rating of 17 at the 6-20 Borg's scale. Running velocity was adjusted after 7 training sessions (during the 3rd week) after reassessment of CV. CV was used to determine the exercise intensity in the CONT group to ensure that all individuals would ran at the heavy intensity domain and be able to complete at least 15 min of continuous running, and to minimize the high inter-individual variations in endurance time at intensities near the upper limit of the heavy intensity domain. Using PTV to determine the intensity in the CONT group, would increase the possibility for trainees to exercise at different exercise intensity domains.
Study: NCT02754856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo liver surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT02334592

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sunbed tanning
Description: Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sunbed tanning
Description: Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sunbed tanning
Description: Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
Study: NCT01433549

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B
Description: Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B
Description: Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A
Description: Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A
Description: Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
Study: NCT01447420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 180 mcg sc weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1'000 or 1'200 mg orally daily, 48 weeks
Study: NCT00268476

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy to the prostate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04024839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Isolated Stretch
Description: In supine position, participant was asked to lock the knee and slowly lift leg using the quadriceps muscles. gentle assistance was given by the rope at the end of the movement, as the quadriceps muscles continue to move the leg. strech was applied for 2 sec and then release to starting position. two sets of 10 repetitions were performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post Isometric Relaxation
Description: In supine line, participant was asked to do SLR until resistance was met in hamstring muscles and then was asked to do isometric contraction (10-20% of maximum) for 5 - 10 sec and inhale. After this, patient was asked to exhale while doing so gentle stretch was applied till the new barrier. Starting from this new barrier, the procedure was repeated 2 - 3 times.
Study: NCT01857843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zotalolimus Eluting Stent
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg & Simvastatin 40mg
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin 20mg
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)
Study: NCT03123432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: immunomodulating nutrients enriched diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard diet
Study: NCT03111537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarettes
Description: Smoke their usual brand of cigarettes and follow their normal patterns of use.
Study: NCT02176408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation
Description: Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Intervention
Description: Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
Study: NCT02105974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: 100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: 25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
Study: NCT00268476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Oestradiol
Study: NCT04672317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy combined with chemotherapy
Description: Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy~Other Names:~• anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy
Study: NCT01118897

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy
Description: Radiotherapy 57-60 Gy in 25 fraction to PTV boost (SIBV - simultaneous integrated Boost volume) (2.3-2.4Gy/Fr)~Concurrent chemotherapy Weekly concurrent CT schedule: Inj Gemcitabine 300 mg/m2 weekly during RT.~Surgery: All patients will be evaluated for surgery in the joint clinic by surgeons and other treating physicians at 6-8 weeks post CT-RT. PET CT Scan will be used as the imaging modality. Patients suitable for R0 resection will be planned for surgery. Inoperable patients will be treated with palliative chemotherapy.
Study: NCT05969613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional block
Description: regional block with 0.25% Bupivacaine at a dose of 2ml/kg with adrenaline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Infiltration of surgical site with 0.25% Bupivacaine at 0.5ml/kg dose

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Infiltration of caudal epidural space with 0.25% Bupivacaine at 1ml/kg dose
Study: NCT02377427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
Study: NCT02697825

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Schiotz tonometer for Intraocular Pressure
Description: Both Values will be corelated
Study: NCT02967744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: NSAIDs are among the most common pain treatments for patients with osteoarthritis.
Study: NCT03387332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
Study: NCT03903276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: Tens
Study: NCT03111537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarette
Description: Use of E-cigarette: multiple flavors offered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarette
Description: Use of E-cigarette: multiple flavors offered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Gum or Lozenge
Description: Subject choice: Use of nicotine gum or nicotine lozenge, multiple flavors offered
Study: NCT02371512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip system (Abbott Vascular, Menlo Park, USA)
Description: Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
Study: NCT02272595

Intervention type: OTHER
Intervention: Treatment Based on Genetic Mutation
Description: Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.

Intervention type: OTHER
Intervention: Treatment Based on No Genetic Mutation
Description: Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
Study: NCT02622308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowOx™
Description: FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
Study: NCT01405248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide
Description: 20 mg/time per os three times a day. 180days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg/time per os three times a day. 180days
Study: NCT02371512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve surgery
Description: Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)